| P50 | author | Sergey Shchelkunov | Q4528657 |
| | Marina A Zenkova | Q99555801 |
| | Julia S Ruzhenkova | Q125216592 |
| P2093 | author name string | Elena P Goncharova | |
| | Ivan S Petrov | |
| P2860 | cites work | Systemic delivery of oncolytic viruses: hopes and hurdles | Q21284969 |
| | New viruses for cancer therapy: meeting clinical needs | Q24567699 |
| | Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy | Q24655930 |
| | The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy | Q26830005 |
| | Trial Watch:: Oncolytic viruses for cancer therapy | Q27021951 |
| | Regulation of human thymidine kinase during the cell cycle | Q28622470 |
| | Emergence and reemergence of vaccinia-like viruses: global scenario and perspectives | Q28709918 |
| | DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis | Q29614217 |
| | IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer | Q29614594 |
| | Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. | Q33769835 |
| | Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor | Q33912043 |
| | Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. | Q33973463 |
| | Oncolytic viruses: From bench to bedside with a focus on safety | Q34044071 |
| | Giving oncolytic vaccinia virus more BiTE. | Q38648659 |
| | Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics | Q38874931 |
| | Antitumor effect of the LIVP-GFP recombinant vaccinia virus. | Q39105286 |
| | Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. | Q39175316 |
| | Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication | Q39840716 |
| | Synergistic antitumor effects of immune cell-viral biotherapy | Q40300577 |
| | Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. | Q40679076 |
| | Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells | Q41115774 |
| | The Toxic Effects of Polychemotherapy onto the Liver Are Accelerated by the Upregulated MDR of Lymphosarcoma. | Q41813332 |
| | Isolation and genetic characterization of human KB cell lines resistant to multiple drugs | Q44844584 |
| | Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage | Q44889298 |
| | Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells | Q45110054 |
| | The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity | Q45411290 |
| | Cellular and humoral immunity against vaccinia virus infection of mice | Q45642985 |
| | IL-6 is required for glioma development in a mouse model | Q47817716 |
| | Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. | Q47831155 |
| | Oncolytic Viral Therapy Using Reovirus. | Q51008265 |
| | CD8 T Cell Help for Innate Antitumor Immunity | Q61295138 |
| | Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay | Q69418921 |
| | Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA | Q72804855 |
| | [Cyclophosphamide-induced apoptosis of murine lymphosarcoma cells in vivo] | Q73497659 |
| | Animal model of drug-resistant tumor progression | Q79886995 |
| | IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma | Q81896185 |
| | Recent clinical experience with oncolytic viruses. | Q34198918 |
| | IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. | Q34452704 |
| | Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. | Q34757261 |
| | Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal | Q35112115 |
| | Oncolytic Poxviruses | Q35234349 |
| | Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity | Q35876239 |
| | Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia | Q35949149 |
| | The immunologic aspects of poxvirus oncolytic therapy | Q36115128 |
| | Features of the Antitumor Effect of Vaccinia Virus Lister Strain | Q36507293 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer | Q36757045 |
| | Vascular endothelial growth factor and its relationship to inflammatory mediators | Q36823246 |
| | Roles of multidrug resistance genes in breast cancer chemoresistance | Q36997383 |
| | Chemoresistance in gliomas | Q37079878 |
| | Primary human leukocyte subsets differentially express vaccinia virus receptors enriched in lipid rafts | Q37123323 |
| | Vaccinia virus, a promising new therapeutic agent for pancreatic cancer | Q37158473 |
| | Vaccinia virus induces programmed necrosis in ovarian cancer cells | Q37316876 |
| | The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys | Q37547241 |
| | Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours | Q37595540 |
| | Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer | Q37734548 |
| | Oncolytic vaccinia virus for the treatment of cancer | Q37845399 |
| | Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression | Q37849716 |
| | Retargeting of viruses to generate oncolytic agents | Q37982062 |
| | Interleukin-6 signaling pathway in targeted therapy for cancer | Q38014987 |
| | Oncolytic viruses in the treatment of cancer: a review of current strategies | Q38020107 |
| | Oncolytic virotherapy | Q38025263 |
| | Strategies for enhancing vaccine-induced CTL antitumor immune responses | Q38055143 |
| | Oncolytic viruses and their application to cancer immunotherapy | Q38207011 |
| | Immunotherapeutic potential of oncolytic vaccinia virus | Q38225561 |
| | Proinflammatory cytokine interleukin-6 in prostate carcinogenesis | Q38265575 |
| | Replicating poxviruses for human cancer therapy | Q38407351 |
| | A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma | Q38425231 |
| | From virotherapy to oncolytic immunotherapy: where are we now? | Q38539862 |
| | Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma | Q38585697 |
| | T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy | Q38648630 |
| P2507 | corrigendum / erratum | Erratum to: Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro. | Q42390333 |
| P433 | issue | 1 | |
| P921 | main subject | phenotype | Q104053 |
| | multiple drug resistance | Q643839 |
| | oncolytic virus | Q1560099 |
| P304 | page(s) | 241 | |
| P577 | publication date | 2016-08-18 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro | |
| P478 | volume | 14 | |